PART I Overview We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects. Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001104659-26-028068 | EDGAR | 95K words |
| 2025-03-25 | 2024-12-31 | 0001558370-25-003588 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001558370-24-003886 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001558370-23-005126 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0001558370-22-003671 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001558370-21-003083 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001558370-20-003257 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-109867 | EDGAR | 61K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011152 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007667 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014767 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001558370-24-011806 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008069 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001558370-23-018572 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001558370-23-014405 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009887 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017205 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001558370-22-013512 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001558370-22-008955 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001104659-26-038258 | EDGAR | 1K words |
| 2026-03-30 | 0001104659-26-036821 | EDGAR | — |
| 2026-03-16 | 0001104659-26-028046 | EDGAR | — |
| 2026-02-18 | 0001104659-26-016797 | EDGAR | — |
| 2026-01-29 | 0001104659-26-007988 | EDGAR | — |
| 2026-01-23 | 0001104659-26-006267 | EDGAR | — |
| 2026-01-09 | 0001104659-26-002490 | EDGAR | — |
| 2025-12-09 | 0001104659-25-119680 | EDGAR | — |
| 2025-11-12 | 0001104659-25-109860 | EDGAR | — |
| 2025-10-24 | 0001104659-25-102004 | EDGAR | — |
139 total filings indexed. 110 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001781983 |
| Ticker | APRE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.aprea.com |
| Listed | 2019-10-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report